Aandeel Biocartis BRU:BCART.BL, BE0974281132

quote:

Berre schreef op 20 oktober 2019 11:36:

ok,heel goed nieuws en als de geautomatiseerde test gelanceerd wordt in het 4de kwartaal 2019,zal alles in een stroomversnelling gaan.het is een gouden aandeel.en wat andere aandelen betreft zoudt u moeten op uw hoede zijn.als buffet het merendeel in cash houdt wil dat toch iets zeggen dat er iets op til is.goud is altijd goed.biocartis is een aandeel die niet onderhevig is aan een crisis,maar buiten deze zijn er nog weinig

quote:

Berre schreef op 20 oktober 2019 12:07:

ik heb u al gezegt zwr dat u geen ballen afweet van de beurs en dat u uw negative kritiek moet stoppen,en alsnog een reactie op flatlander,die vergunningen zijn al afgeleverd

quote:

CGCDLR schreef op 20 oktober 2019 14:15:

@ DZR:,en al die andere forums,waar je er flagrant naast zat, houdt je nu wijselijk je bakkes!Wel hou ze dan voorgoed.

quote:

CGCDLR schreef op 20 oktober 2019 15:06:

1@DZ;Tuurlijk knuppel.Blij jij maar aan de Cannabis.Na je missers met Tigenix,Ablynx,Galapagos,en,...... ,is dit je enige uitweg.Zielig.

quote:

Flatlander schreef op 21 oktober 2019 05:00:

I miss a lot in the translation of the previous messages but I'd like to add my perspective of why I have jumped a lot of hurdles to invest in BCART. I see BCRT as being situated at the intersection of personalized medicine and automation. Like Apple, BCART is heavily dependent on its development partners. My belief is that one of them will launch a Killer Ap that will drive idylla console and cartridge sales. I think OncoDX Breast and Seticyte are strong candidates.

I can agree with DZR that a high percentage of biotechs fail. But the rate of failure decreases with the number of product launches. BCART is pushing 10 products, with numerous others in development. Under these circumstances the potential for failure is greatly reduced.
FL

quote:

Berre schreef op 21 oktober 2019 09:56:

zijt u op pensioen zwr of wilde gij niet gaan werken,of bent u ontslagen omdat u een leeg hoofd zijt,speel elders en ga uw wijsheden elders verkopen

quote:

Flatlander schreef op 21 oktober 2019 14:41:

DZR

Costs are all relative. What BCART charges for a pack of 6 cartridges is much less than a similar test run on the Foundation/Roche platform. It also has advantages in a much lower TAT (hrs instead of weeks) and it requires less personnel and space requirements. How much does it cost to not run any MDx and prescribe the wrong ineffective medication? As far as the costs, BCART is trading at a similar market capitalization as when it went public. They now have around 10 approved products, two cartridge manufacturing lines, and a worldwide sales footprint. There are dozens of favorable product reviews. Arguably all of those factors add considerably more value than when BCART IPOd.
FL

quote:

Flatlander schreef op 21 oktober 2019 14:41:

DZR

Costs are all relative. What BCART charges for a pack of 6 cartridges is much less than a similar test run on the Foundation/Roche platform. It also has advantages in a much lower TAT (hrs instead of weeks) and it requires less personnel and space requirements. How much does it cost to not run any MDx and prescribe the wrong ineffective medication? As far as the costs, BCART is trading at a similar market capitalization as when it went public. They now have around 10 approved products, two cartridge manufacturing lines, and a worldwide sales footprint. There are dozens of favorable product reviews. Arguably all of those factors add considerably more value than when BCART IPOd.

FL